Expert Interview
Discussing current commercial use of Ayvakit and the ongoing SUMMIT trial evaluating bezuclastinib in iSM (indolent systemic mastocytosis)
Ticker(s): COGT, BPMCInstitution: Scripps Clinic
- Allergist/Immunologist & Director, Aspirin Exacerbated Respiratory Disease Clinic,Division of Allergy, Asthma and Immunology at the Scripps Clinic.
- Currently manages 35 patients with systemic mastocytosis.
- Focus is on Aspirin exacerbated respiratory disease (AERD), mastocytosis, and mast cell activation syndromes; conducts research on aspirin exacerbated respiratory disease, a topic on which he has authored multiple publications and ongoing research protocols.
How many iSM patients do you have on Ayvakit?
Added By: wilson_adminHow concerning is the AE profile seen in bezuclastinib, in particular the liver signal and diarrhea?
Added By: wilson_adminWhat would you need to see in the SUMMIT trial to justify use of bezuclastinib over Ayvakit?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
